All News

Simple steps to minimize risk are easily overlooked when pharmacies get busy.

Many drugs for these conditions enter clinical trials, but few demonstrate success.

DaxibotulinumtoxinA-lanm from Revance Therapeutics Inc is the first peptide-formulated neuromodulator with long-lasting results.

Using your voice as a health care professional and supporting each other through burnout are just a few ways to better advocate in the profession.

Eflapegrastism-xnst injection (Rolvedon, Spectrum Pharmaceuticals) is indicated to lower the incidence of infection, as demonstrated by febrile neutropenia, in adult patients with non-myeloid malignancies.

Researchers found differences in the variable importance of cancer mortality risk factors depending on an individual’s geographical region.

The drug improves kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

Researchers found that patients diagnosed with early-onset type 2 diabetes have a greater risk of premature death than the general population.

Prior authorizations have delayed time to treatment for patients and can directly impact clinical outcomes.

Panelists discuss pharmacist involvement in effective management, including disease burden and quality of life.

Deucravacitinib is a selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, which is a member of the Janus kinase (JAK) family.

Alopecia areata is an autoimmune disease with an underlying immuno-inflammatory pathogenesis.

Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.

Pharmacists should ascertain whether self-treatment is appropriate and suggest medical care if it isn’t.

Services such as managing/updating patient programs and working with non-profits can go a long way in healthcare education for patients.

Part A results from the 2-part LILAC study show that the therapy significantly reduced disease activity based on active joint count in individuals compared with the placebo.

Researchers have identified hydroquinine as a potential treatment against drug-resistant bacteria, which can cause infections with a 70% mortality rate.

Study suggests gene therapy may effectively treat young children who were born colorblind via pathways connecting the brain and the retina.

Many health care systems use these products to provide similar but cheaper clinical outcomes.

Research suggests that subcutaneous insulin aspart is a cost-effective and accessible treatment option that could allow children with type 1 diabetes to avoid the ICU after a mild episode of diabetic ketoacidosis.

The long-acting, once-daily hormone controls high blood sugar in individuals aged 1 year or older with diabetes.

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

Research indicates that poor technique or failure to follow up-to-date standards and protocols could lead to injury or even death of patients who need compounded medications.

Key responsibilities include providing recommendations, administering vaccinations, disseminating evidence-based advice, reducing spread of influenza in communities.

Excess drinking is a major atrial fibrillation risk factor in young people.

ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.

Investigators find 8 of 10 of the most common symptoms were reported between 50% and 80% less often among those who received at least 2 Pfizer-BioNTech vaccinations.

Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.

It is currently indicated for the treatment of adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.